Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin.

Schlegel PN, Kuzma P, Frick J, Farkas A, Gomahr A, Spitz I, Chertin B, Mack D, Jungwirth A, King P, Nash H, Bardin CW, Moo-Young A

Urology1 Oct 2001Cited by 22 (Europe PMC)

PMID11597543DOI10.1016/s0090-4295(01)01293-6PepBankPUB-11597543

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
Among 38 assessable men receiving histrelin hydrogel implants, 35 (92%) achieved castrate testosterone within 4 weeks.
In plain wordsAmong 38 assessable men receiving histrelin hydrogel implants, 35 (92%) achieved castrate testosterone within 4 weeks.
Peptide
Histrelin
Outcome
Not applicableCastrate testosterone within 4 weeks
Study
n = 38
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
one, two, or four implants · implantAs given in this study (human).
Measurements
Patients with castrate testosterone
35 patients
within 4 weeks of initial implant placement, of 38 assessable
Proportion with castrate testosterone
92%
within 4 weeks of initial implant placement, of 38 assessable
Source sentences
Summary
Of the 38 assessable patients, 35 (92%) had castrate levels of testosterone within 4 weeks of the initial implant placement.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-two men with prostate cancer and indications for androgen ablation were treated with one, two, or four implants.
Report a problemFND-1159754305
02HumanNon-randomized trialPharmacokinetics
In men with prostate cancer, serum histrelin levels were proportional to the number of hydrogel implants placed (one, two, or four).
In plain wordsIn men with prostate cancer, blood histrelin levels rose with the number of implants placed.
Peptide
Histrelin
Outcome
IncreaseSerum histrelin by implant number
Study
n: not reported in source
Comparator
Different implant numbers (one, two, or four)
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
one, two, or four implants · implantAs given in this study (human).
Source sentences
Summary
The histrelin levels were detected in serum proportional to the number of implants placed.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-two men with prostate cancer and indications for androgen ablation were treated with one, two, or four implants.
Report a problemFND-1159754301
03HumanNon-randomized trialEfficacy outcome
In prostate cancer patients, one, two, or four histrelin hydrogel implants essentially completely suppressed testosterone, with similar responses across doses.
In plain wordsIn prostate cancer patients, one, two, or four histrelin hydrogel implants essentially completely suppressed testosterone, with similar responses across doses.
Peptide
Histrelin
Outcome
Direction not reportedTestosterone response across doses
Study
n: not reported in source
Comparator
Other implant dose levels
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
one, two, or four implants · implantAs given in this study (human).
Source sentences
Summary
The response, however, was similar among all three dose levels, with testosterone and luteinizing hormone essentially completely suppressed.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-two men with prostate cancer and indications for androgen ablation were treated with one, two, or four implants.
Report a problemFND-1159754302
04HumanNon-randomized trialEfficacy outcome
In prostate cancer patients, one, two, or four histrelin hydrogel implants essentially completely suppressed LH, with similar responses across doses.
In plain wordsIn prostate cancer patients, one, two, or four histrelin hydrogel implants essentially completely suppressed LH, with similar responses across doses.
Peptide
Histrelin
Outcome
Direction not reportedLH response across doses
Study
n: not reported in source
Comparator
Other implant dose levels
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
one, two, or four implants · implantAs given in this study (human).
Source sentences
Summary
The response, however, was similar among all three dose levels, with testosterone and luteinizing hormone essentially completely suppressed.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-two men with prostate cancer and indications for androgen ablation were treated with one, two, or four implants.
Report a problemFND-1159754303
05HumanNon-randomized trialEfficacy outcome
In men with prostate cancer, serum testosterone fell from 21.9 +/- 17.6 nmol/L to 0.93 +/- 1.57 nmol/L within 1 month with histrelin hydrogel implants, and was 0.55 +/- 0.24 nmol/L at 6 months and 0.60 +/- 0.28 nmol/L after 12 months.
In plain wordsIn prostate cancer patients, histrelin hydrogel implants reduced testosterone within 1 month and maintained low levels through 12 months.
Peptide
Histrelin
Outcome
DecreaseTestosterone trajectory
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
one, two, or four implants · implantAs given in this study (human).
Measurements
Serum testosterone, mean
21.9 nmol/L
baseline
Serum testosterone, +/- as written
17.6 nmol/L
baseline
Serum testosterone, mean
0.93 nmol/L
within 1 month
Serum testosterone, +/- as written
1.57 nmol/L
within 1 month
Serum testosterone, mean
0.55 nmol/L
6 months
Serum testosterone, +/- as written
0.24 nmol/L
6 months
Serum testosterone, mean
0.6 nmol/L
after 12 months of treatment
Serum testosterone, +/- as written
0.28 nmol/L
after 12 months of treatment
Source sentences
Summary
Serum testosterone levels decreased from 21.9 +/- 17.6 nmol/L to 0.93 +/- 1.57 nmol/L within 1 month and were maintained at 0.55 +/- 0.24 nmol/L at 6 months and 0.60 +/- 0.28 nmol/L after 12 months of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-two men with prostate cancer and indications for androgen ablation were treated with one, two, or four implants.
Report a problemFND-1159754304
06HumanNon-randomized trialEfficacy outcome
All men followed for 12 months maintained testosterone suppression while their initial histrelin hydrogel implants remained present.
In plain wordsAll men followed for 12 months maintained testosterone suppression while their initial histrelin hydrogel implants remained present.
Peptide
Histrelin
Outcome
Not applicableTestosterone suppression maintained at 12 months
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
one, two, or four implants · implantAs given in this study (human).
Source sentences
Summary
All patients followed for up for 12 months after placement of the initial set of implants maintained suppression of testosterone production while the implant was in place.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-two men with prostate cancer and indications for androgen ablation were treated with one, two, or four implants.
Report a problemFND-1159754306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.